are an ‘‘emerging growth company’’ as defined under the U.S. federal securities laws and, as such, intend to comply with certain reduced public company reporting requirements for this and future filings.The underwriters have an option to purchase a maximum of 900,000 additional shares.Investing in our common stock involves risks.
commercialization to bring first-in-class and best-in-class monoclonal antibody therapeutics to patients who are underserved by current therapies.Key elements of our strategy include:•advance and commercialize ALD403 for the prevention of migraine;•seek a partner to advance and commercialize Clazakizumab as an option for first-line biologic therapy in autoimmune and inflammatory disease;-4-Table of Contents•advance ALD1613 for the treatment of Cushing’s Disease;•leverage our technology platform to discover future product candidates for areas of unmet need; and•build a leading biopharmaceutical company to transform current treatment paradigms.Risks Related to Our BusinessOur business is subject to numerous risks and uncertainties, including those highlighted in the section of this prospectus titled “Risk Factors” immediately following this prospectus summary.
30,2012201320132014(in thousands, except share and per share data)Consolidated Statements of Operations Data:Revenues:Collaboration and license agreements$20,067$18,796$13,972$48,269Operating expenses:Research and development30,66931,88325,54923,444General and administrative7,2177,6745,3219,054Total operating expenses37,88639,55730,87032,498Income (loss) from operations(17,819)(20,761)(16,898)15,771Other income (expense):Interest income101544730Other income—15815849Interest expense(88)———Other expense—(64)(45)—Total other income1314816079Net income (loss)$(17,806)$(20,613)$(16,738)$15,850Net income (loss) per share—basic$(19.54)$(21.14)$(17.21)$0.93Net income (loss) per share—diluted$(19.54)$(21.14)$(17.21)$0.56Weighted average number of common shares used in net loss per share—basic911,354975,158972,62417,006,362Weighted average number of common shares used in net loss per share—diluted911,354975,158972,62428,240,947-7-Table of ContentsAs of September 30, 2014ActualAs Adjusted(1)(2)(in thousands)Consolidated Balance Sheet Data:Cash, cash equivalents and investments$67,583$238,980Working capital63,052234,449Total assets75,824247,221Total liabilities10,91610,916Accumulated deficit(129,964)(129,964)Total stockholders’ equity64,908236,305(1)The as adjusted column reflects the sale of 6,000,000 shares of our common stock in this offering at an assumed public offering price of $30.48 per share, which is the
As a result, the trading price of our common stock could decline and you could lose part or all of your investment.Risks Related to Our Business and the Development and Commercialization of Our Product CandidatesWe have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable future.We are a clinical-stage biopharmaceutical company.
that our expenses will increase substantially as we:•continue the research and development of our product candidates, including clinical trials of ALD403;•seek regulatory approvals for our product candidates that successfully complete clinical trials;•establish a sales, marketing and distribution infrastructure and scale-up manufacturing capabilities to commercialize ALD403 or any of our future
depends on our and any of our future collaborators’ success in:•completing clinical development and obtaining regulatory approval for ALD403;•entering into collaboration agreements with third parties with respect to our product candidates, including ALD403 and Clazakizumab, for their
development and commercialization in the United States or in international markets, and the continued financial and other support of these third parties under such collaboration agreements;•launching and commercializing ALD403, if approved, and successfully establishing sales, marketing and distribution infrastructure;•obtaining regulatory approvals for future product candidates that we discover and successfully develop;•establishing and maintaining supply and manufacturing relationships with third parties;•obtaining coverage and adequate reimbursement from third-party payors; and•maintaining, protecting, expanding and enforcing our intellectual property, including intellectual property we license from third parties.Because of the numerous risks and uncertainties associated with biologic product development, we are unable
including the following:•our ability to successfully complete this offering;•the rate of progress, recruitment and cost of our clinical trials and clinical success for ALD403 and any future product candidates;•the timing of, and costs involved in, seeking and obtaining approvals from the FDA and other regulatory authorities;•the costs of commercialization activities if any of our product candidates, such as ALD403, receive regulatory approval, including sales, marketing and
Because successful-11-Table of Contentsdevelopment of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and commercialize our product candidates.Furthermore, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe
The success of these product candidates will depend on several factors, including the following:•successful enrollment in, and completion of, clinical trials;•our ability to reach agreements with the FDA and other regulatory authorities on the appropriate regulatory path for approval for ALD 403;•receipt of approvals from the FDA and similar regulatory authorities outside the United States for these product candidates;•establishing commercial manufacturing arrangements with third parties;•successfully launching sales, marketing and distribution of any product candidate that may be approved, whether alone or in collaboration with others;•acceptance of any approved product by the medical community, third-party payors and patients and others involved in the reimbursement process, such as
the Centers for Medicare and Medicaid Services in the United States and the National Institute of Clinical Excellence in the United Kingdom;•effectively competing with other therapies;•achieving a continued acceptable safety profile of the product following approval, including intellectual property we license from third parties; and•obtaining, maintaining, enforcing and defending intellectual property rights and claims.If we do not achieve one or more of these factors in a timely manner, or at all, we could experience significant delays or an inability to
the data from our or BMS’s U.S. clinical trials, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt the development of a product candidate.The development and commercialization of biologic products is subject to extensive regulation, and we may not obtain regulatory
for many reasons, including because they:•may not deem the product candidate to be adequately safe or effective;•may not find the data from preclinical studies, clinical trials or CMC data to be sufficient to support a claim of safety and efficacy;•may not approve the manufacturing processes or facilities associated with the product candidate;-14-Table of Contents•may conclude that the long-term stability of the formulation of the drug product for which approval is being sought has been sufficiently demonstrated;•may change approval policies or adopt new regulations; or•may not accept a submission due to, among other reasons, the content or formatting of the submission.To market any biologics outside of the United States, we and any of our future collaborators must comply with the numerous and varying
if approved for commercial sale, will depend on a number of factors, including the following:•the efficacy and potential advantages compared to alternative treatments;•the prevalence and severity of any side-effects;•the price we or any of our future collaborators charge for our products;•the availability of third-party coverage and adequate reimbursement;•the convenience and ease of administration compared to alternative treatments;•the willingness of the target patient population to try new therapies and of physicians to prescribe these new therapies; and•the size and effectiveness of our sales, marketing and distribution support.If our product candidates are approved and do not achieve an adequate level of acceptance, we may not generate significant product
future collaborators’ inability to promptly obtain coverage and profitable payment rates from both government funded and private payors-19-Table of Contentsfor newly developed products could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.We may not be successful in our efforts to use and enhance our proprietary antibody platform to create a pipeline of
In addition, failure to comply with FDA and other applicable U.S. and foreign regulatory requirements may subject us to administrative or judicially imposed sanctions, including the following:•warning letters;•civil or criminal penalties and fines;•injunctions;•suspension or withdrawal of regulatory approval;•suspension of any ongoing clinical trials;•voluntary or mandatory product recalls and publicity requirements;•refusal to accept or approve applications for marketing approval of new drugs or biologics or supplements to approved applications filed by us;•restrictions on operations, including costly new manufacturing requirements; or•seizure or detention of our products or import bans.Prior to receiving approval to commercialize any of our product candidates in the United States or abroad, we and any of our future collaboration partners must demonstrate with substantial evidence from